A phase Ib/2 clinical trial that combined BET inhibitor ZEN-3694 and talazoparib showed a response rate of 22% in patients with triple-negative breast cancer without germline BRCA1/2 mutations [45]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.